Pharmacological management of stable COPD;Medikamentöses management der stabilen COPD

Wiener Medizinische Wochenschrift

Volumn 155, Issue 5-6, 2005, Pages 95-100

  Rauscher, Helmuth ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

Author keywords

COPD; COPD pharmacotherapy; COPD therapy guidelines

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; ANTIBIOTIC AGENT; ANTITUSSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FENOTEROL; GLUCOCORTICOID; IMMUNOMODULATING AGENT; METHYLXANTHINE; MUCOLYTIC AGENT; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE; VACCINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; EXERCISE TOLERANCE; HEALTH STATUS; HUMAN; QUALITY OF LIFE; REVIEW; SYMPTOM;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; EXPECTORANTS; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; TIME FACTORS; XANTHINES;

EID: 17444396308     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-005-0155-7     Document Type: Review

References (34)

1. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272: 1497-1505
2. Aubier M (1988) Pharmacotherapy of respiratory muscles. Clin Chest Med 9: 311-324
3. Belman MJ, Botnick WC, Shin JW (1996) Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153: 967-975
4. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C (1997) An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 10: 815-821
5. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: 1297-1303
6. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361: 449-456
7. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19: 217-224
8. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A (1997) Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 156: 1719-1724
9. COMBIVENT Inhalation Aerosol Study Group (1994) In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 105: 1411-1419
10. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease I Study Group (2001) Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 778-784
11. Decramer M, Lacquet LM, Fagard R, Rogiers P (1994) Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 150: 11-16
12. Disse B, Speck GA, Rominger KL, Witek TJ, Jr., Hammer R (1999) Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64: 457-464
13. GOLD Executive Summary (2003) Global strategy for the diagnosis, management and prevention of COPD. Published online: www.goldcopd.com
14. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF (1989) Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 139: 1188-1191
15. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, Newhouse MT (1987) Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 135: 1069-1074
16. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverley PM (1992) Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 5: 659-664
17. Higgins BG, Powell RM, Cooper S, Tattersfield AE (1991) Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 4: 415-420
18. Irwin RS, Boulet LP, Cloutier MM, Fuller R, Gold PM, Hoffstein V, Ing AJ, McCool FD, O'Byrne P, Poe RH, Prakash UB, Pratter MR, Rubin BK (1998) Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 114: 133S-181S
19. Jones PW, Willits LR, Burge PS, Calverley PM (2003) Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21: 68-73
20. Johnston RN, McNeill RS, Smith DH, Dempster MB, Nairn JR, Purvis MS, Watson JM, Ward FG (1969) Five-year winter chemoprophylaxis for chronic bronchitis. Br Med J 4: 265-269
21. Lipworth BJ, McDevitt DG, Struthers AD (1990) Hypokalemic and ECG sequelae of combined beta-agonist/diuretic therapy. Protection by conventional doses of spironolactone but not triamterene. Chest 98: 811-815
22. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH (1999) Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115: 957-965
23. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ (1993) Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 48: 227-232
24. Murciano D, Auclair MH, Pariente R, Aubier M (1989) A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 320: 1521-1525
25. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T (1994) The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331: 778-784
26. Österreichische Gesellschaft für Lungenerkrankungen und Tuberkulose (2004) Konsensus zum Management der chronisch obstruktiven Lungenerkrankungen (COPD). Wien Klin Wochenschr 116: 268-278
27. Pauwels RA, Lofdahl CG, Laitinen LA, Scheuten JP, Postma DS, Pride NB, Ohlsson SV (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340: 1948-1953
28. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Delia Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group (2002) Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121: 1058-1069
29. Senderovitz T, Vestbo J, Frandsen J, Maltbaek N, Norgaard M, Nielsen C, Kampmann JP (1999) Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med 93: 715-718
30. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al (1995) Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 8: 1398-1420
31. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21: 74-81
32. The COMBIVENT Inhalation Solution Study Group (1997) Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 112: 1514-1521
33. The Lung Health Study Research Group (2000) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: Lung Health Study II. N Engl J Med 343: 1902-1909
34. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ; Dutch/Belgian Tiotropium Study Group (2002) Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19: 209-216